Irma, Maria highlight pharma's need to balance supply chain

31 October 2017

An expert view piece by Steven Shill, Patrick Pilch and David Friend from the BDO Center for Healthcare Excellence & Innovation, on what drug manufacturers should watch in the wake of natural disasters.

When it comes to natural disasters, it’s not about if your supply chain will be impacted, it’s when.

For the life sciences industry, the consequences of supply chain disruption become a public safety concern. Like 1998’s Hurricane George, Hurricanes Irma and Maria have underlined this concern. Following the storms, the Food and Drug Administration (FDA) announced that the USA will likely experience drug shortages due to the natural disasters’ residual impact on the drug manufacturing industry in Puerto Rico.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK